Our data indicated that CC treatment could improve obesity, insulin resistance, hyperlipidemia and non-alcoholic fatty liver disease (NAFLD) disease in diet-induced obesity (DIO) mice as a novel PPARγ antagonist. This evidence concerns the gene PPARG and obesity disorder.